Acadia appoints Brendan Teehan as EVP, COO, Head of Commercial; two executives depart

ACADIA PHARMACEUTICALS INC

Brendan Teehan promoted to EVP, Chief Operating Officer and Head of Commercial, effective immediately.
Teehan previously SVP, Chief Insights and Analytics Officer; will lead all sales and marketing functions.
Charmaine Lykins (SVP, Global Product Planning) and Amanda Morgan (SVP, Chief Revenue) leaving after transition period.
Teehan has over 25 years healthcare experience, previously at Johnson & Johnson, Amgen, TESARO.
Appointment comes as Acadia prepares for next phase of growth, per CEO Steve Davis.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brendan P. Teehan

Executive Vice President, Chief Operating Officer and Head of Commercial

ACAD · ACADIA PHARMACEUTICALS INC

Effective: 2021-11-01
Filed: November 5, 2021, 7:59 PM ET

On November 1, 2021, the Board of Directors of Acadia Pharmaceuticals Inc. (the “Company”) appointed Brendan P. Teehan as Executive Vice President, Chief Operating Officer and Head of Commercial and as the Company’s principal operating officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brendan P. Teehan was appointed as Executive Vice President, Chief Operating Officer and Head of Commercial at ACADIA PHARMACEUTICALS INC.

Action: appointed
Role: Executive Vice President, Chief Operating Officer and Head of Commercial

Exact text from the filing

On November 1, 2021, the Board of Directors of Acadia Pharmaceuticals Inc. (the “Company”) appointed Brendan P. Teehan as Executive Vice President, Chief Operating Officer and Head of Commercial and as the Company’s principal operating officer.

View on SEC.gov

ACADIA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-21-321667

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.